Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

BACKGROUND: The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverberg, Jonathan I., Adam, David N., Zirwas, Matthew, Kalia, Sunil, Gutermuth, Jan, Pinter, Andreas, Pink, Andrew E., Chiricozzi, Andrea, Barbarot, Sebastien, Mark, Thomas, Tindberg, Ann-Marie, Weidinger, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334431/
https://www.ncbi.nlm.nih.gov/pubmed/35857179
http://dx.doi.org/10.1007/s40257-022-00702-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334431/
https://www.ncbi.nlm.nih.gov/pubmed/35857179
http://dx.doi.org/10.1007/s40257-022-00702-2

Ejemplares similares